Market Newsdesk

November 25, 2020 8:11 am

Bio-Thera Solutions Submits Marketing Authorization Application (MAA) for BAT1706, a Proposed Biosimilar to Avastin®, to European Medicines Agency (EMA)

Bio-Thera Solutions Submits Marketing Authorization Application (MAA) for BAT1706, a Proposed Biosimilar to Avastin^®, to European Medicines Agency (EMA)

GUANGZHOU, China–(BUSINESS WIRE)–
Bio-Thera Solutions (SHA: 688177), a commercial-stage biopharmaceutical company, today announced that it has submitted the MAA for BAT1706, a proposed biosimilar to Avastin^® (bevacizumab), to EMA. Bio-Thera seeks a commercial license for all approved indications of bevacizumab in the European Union (EU) Member States, Iceland, Norway and Liechtenstein.

“The submission of the MAA for BAT1706 marks a milestone for Bio-Thera as the first ex-China MAA or BLA submission,” said Dr. Shengfeng Li, Founder and CEO of Bio-Thera Solutions. “Bio-Thera intends to bring its pipeline of biosimilars and innovative therapies to patients around the world and this submission is an important step for extending the global reach of BAT1706”.

BAT1706 is a proposed bevacizumab biosimilar developed by the company. Bevacizumab is a humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF). It can specifically bind to VEGF and block the binding of VEGF to its receptor, thereby reducing neovascularization, inducing the degradation of existing blood vessels, and thereby inhibiting tumor growth. Bevacizumab has been approved in Europe for the treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer, non–small cell lung cancer, advanced or metastatic renal cell cancer, epithelial ovarian, fallopian tube and primary peritoneal cancer, and cervical cancer.

A Biologics License Application seeking approval for BAT1706 for the treatment of metastatic carcinoma of the colon or rectum and non–small cell lung cancer is under review by the China National Medicinal Product Administration (NMPA). Bio-Thera intends to submit a BLA for BAT1706 to the U.S. Food and Drug Administration (FDA) before the end of 2020.

BAT1706 is Bio-Thera Solutions’ second proposed biosimilar submitted for regulatory approval. The company’s first biosimilar product, QLETLI^® (格乐立^®), a biosimilar to Humira^® (adalimumab), has received marketing authorization and is available in China. Bio-Thera Solutions is developing several additional proposed biosimilars, including golimumab, ustekinumab and secukinumab, and mepolizumab among others.

About BAT1706

BAT1706 is a monoclonal antibody that is in development as a potential biosimilar to Avastin^®. BAT1706 works by binding the vascular endothelial growth factor (VEGF) protein. In the EU, Avastin^® is indicated for the treatment of patients with metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, persistent, recurrent, or metastatic cervical cancer, and epithelial ovarian, fallopian tube, or primary peritoneal cancer. BAT1706 is an investigational compound and has not received regulatory approval in any country.

About Bio-Thera Solutions

Bio-Thera Solutions, Ltd., a leading commercial-stage biopharmaceutical company in Guangzhou, China, is dedicated to researching and developing novel therapeutics for the treatment of cancer, autoimmune, cardiovascular diseases, and other serious unmet medical needs, as well as biosimilars for existing, branded biologics to treat a range of cancer and autoimmune diseases. As a leader in the next generation antibody discovery and engineering, the company has advanced five candidates into late stage clinical trials and one of which, QLETLI^® (格乐立^®), a biosimilar to Humira^® (adalimumab), is available to patients with rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, Crohn’s disease and uveitis indications in China. In addition, the company has multiple candidates in early clinical trials and IND-enabling studies, focusing on innovative targets in immuno-oncology and autoimmune diseases. For more information, please visit www.bio-thera.com/en/ or follow us on Twitter (@bio_thera_sol) and wechat (Bio-Thera).

Bio-Thera’s Notes Regarding Forward-Looking Statements

This press release contains certain forward-looking statements relating to BAT1706 or Bio-Thera Solutions and its product pipeline in general. Readers are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. The forward-looking statements include, among others, those containing “will,” “would,” “could,” “may,” “potential,” “promising,” “plans,” “expected,” or similar expressions. They reflect Bio-Thera Solutions’ current views with respect to future events that are based on what the company believes are reasonable assumptions in view of information available to Bio-Thera Solutions as of the date of this press release and are not a guarantee of future performance or developments. Actual results and events may differ materially from information contained in the forward-looking statements as a result of a number of factors, including, but not limited to, risks and uncertainties inherent in pharmaceutical research, development and commercialization, such as the risks and uncertainties of pre-clinical and clinical studies, and in obtaining regulatory approvals. Other risk factors include risks and uncertainties in manufacturing, distribution, marketing, competition, intellectual property, product efficacy or safety, changes in national and global financial and healthcare situations, changes in the company’s financial conditions, and changes to applicable laws and regulations, etc. Forward-looking statements contained herein are made only as of the date of their initial publication, Bio-Thera Solutions undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, changes in the company’s views or otherwise.

1 Avastin^® is a registered trademark of Genentech, Inc.

2 QLETLI^® is a registered trademark of Bio-Thera Solutions, Ltd.

3 Humira^® is a registered trademark of Abbvie, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201125005461/en/

Bio-Thera Solutions, Ltd.:

Bert E. Thomas IV +1.410.627.1734

[email protected]

KEYWORDS: Asia Pacific Europe China Iceland Norway

INDUSTRY KEYWORDS: Biotechnology Technology Health General Health Pharmaceutical Oncology Other Science Other Technology Research Science Clinical Trials

MEDIA:

Logo

November 25, 2020 8:08 am

Condos Are Selling for a Record 17% Discount to Single-Family Homes as the Coronavirus Fuels Demand for Space

The desire for privacy during the pandemic is keeping a lid on condo prices, but condo sales are up 23%–on par with sales growth for single-family homes–as buyers take advantage of the discounts

PR Newswire

SEATTLE, Nov. 25, 2020 /PRNewswire/ — (NASDAQ: RDFN) — The typical single-family home that sold in the U.S. this year was purchased for an average of 17.3% more ($58,000) than the typical condo, according to a new report from Redfin (www.redfin.com), the technology-powered real estate brokerage. That’s up from 15.4% last year and represents the largest premium since at least 2013, when Redfin began recording this data.

The U.S. housing market has been on fire this year, with record-low mortgage rates and remote work prompting scores of Americans to relocate. But the condo market has missed out on much of the gains as homebuyers have left dense cities in search of more space and privacy—AKA single-family homes—during the coronavirus pandemic.

The median sale price of single-family homes surged 15.5% year over year in October, outpacing the condo market’s 9.9% growth. Condos are also taking longer to sell—the typical condo spent 36 days on the market last month, compared with 27 days for the typical single-family home. And less than a quarter (22.8%) of condos sold for more than their listing price, compared with 36.6% of single-family homes.

Purchases of condos, however, have been catching up. In October, condo sales rose 22.7% from a year earlier on a seasonally-adjusted basis, following a 50% plunge in the spring. That’s on par with the 23.3% growth in sales of single-family homes last month.

“Condos sales are rebounding because buyers are finding great deals,” said Redfin Chief Economist Daryl Fairweather. “Families are fleeing cities in search of more space in the suburbs, which has presented an opportunity for millennials who are looking to become homeowners but don’t need extra bedrooms or a backyard.”

October 2020 Market Summary: Single-Family Homes Vs Condos

	Single-family homes	Condos
Median sale price	$350,000 (+15.5% YoY)	$277,000 (9.9% YoY)
Median days on market	27 (-17 days YoY)	36 (-7 days YoY)
Share of properties that sold above list price	36.6%	22.8%
Share of properties that faced bidding wars	59.8%	42.6%
Year-over-year change in supply (active listings)	-27.0%	5.2%
Year-over-year change in homes sold (seasonally adjusted)	23.3%	22.7%

Florida and California Rank at the Top of the List When It Comes to Price Premiums for Single-Family Homes

In the Fort Lauderdale, FL metropolitan area, single-family homes sold for an average of 38.3% more than condos in October—the largest premium of the 86 metros in this analysis. It was followed by Bakersfield, CA, with a 35.8% premium, and Lakeland, FL, at 34.3%. Oklahoma City, OK and Tucson, AZ rounded out the top five, both at 30.3%.

In the Seattle metro, where single-family homes are selling for a 17.9% premium, condos are taking several months to sell rather than the usual couple of weeks, according to local Redfin real estate agent Forrest Moody.

“Before the pandemic, it was challenging to find a condo in Seattle for less than $500,000, but now there are plenty selling for under $400,000. The people who are buying condos now are the people who couldn’t afford to buy one a couple of years ago because prices were so high,” he said. “I recently sold a condo that was within walking distance of Amazon’s headquarters for $510,000. Condos in that building normally go for $550,000 and up.”

There were just three metro areas where single-family homes sold for less than condos in October. San Antonio saw the biggest gap, with single-family homes going for 12.9% less than condos, followed by Omaha, NE (-6.2%) and Salt Lake City (-1.7%).

In San Antonio, there’s been a resurgence of high-end condos in the downtown area, according to local Redfin real estate agent Jim Seifert.

“There are more people buying condos in San Antonio than I’ve ever seen before,” Seifert said. “Young people who work in tech and healthcare are moving here from Seattle, California, Washington, D.C. and Maryland because San Antonio is so much more affordable, and they have a bigger appreciation for downtown living than the average person from Texas.”

Seifert continued: “San Antonio’s condo market is also likely being fueled by the fact that buyers know they can get in. There’s a shortage of single-family homes for sale, but the supply of condos is growing like wildfire, so some folks are opting for condos because they don’t want to deal with a bidding war.”

To read the full report, including methodology and a full list of single-family home price premiums across major U.S. metro areas, please visit: https://www.redfin.com/news/single-family-home-premium-condo.

About Redfin
Redfin (www.redfin.com) is a technology-powered residential real estate company, redefining real estate in the consumer’s favor in a commission-driven industry. We do this by integrating every step of the home buying and selling process and pairing our own agents with our own technology, creating a service that is faster, better and costs less. We offer brokerage, iBuying, mortgage, and title services, and we also run the country’s #1 real estate brokerage search site, offering a host of online tools to consumers, including the Redfin Estimate. We represent people buying and selling homes in over 90 markets in the United States and Canada. Since our launch in 2006, we have saved our customers over $800 million and we’ve helped them buy or sell more than 235,000 homes worth more than $115 billion.

For more information or to contact a local Redfin real estate agent, visit www.redfin.com. To learn about housing market trends and download data, visit the Redfin Data Center. To be added to Redfin’s press release distribution list, email [email protected]. To view Redfin’s press center, click here.

View original content to download multimedia:http://www.prnewswire.com/news-releases/condos-are-selling-for-a-record-17-discount-to-single-family-homes-as-the-coronavirus-fuels-demand-for-space-301180334.html

SOURCE Redfin

November 25, 2020 8:08 am

E*TRADE Corporate Services Study Reveals Employees Place Greater Emphasis on Equity Compensation Amid Pandemic

E*TRADE Corporate Services Study Reveals Employees Place Greater Emphasis on Equity Compensation Amid Pandemic

In a challenging year, participants are increasingly engaged with their stock plans

ARLINGTON, Va.–(BUSINESS WIRE)–
E*TRADE Corporate Services, a division of Morgan Stanley at Work, today announced results from its annual survey of equity compensation plan participants.¹

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201125005593/en/

(Graphic: Business Wire)

E*TRADE interviewed 53,512 stock plan participants from September 8–18, 2020, seeking their views on how they engage with, and feel about, their equity compensation. Results show that in this volatile and uncertain year participants across all ages and categories placed higher importance on—and satisfaction with—their stock plan benefits:

As the workplace goes digital, participants are more plugged in: With many working remote, more participants are checking in on their stock plans weekly, up 7 percentage points, and logging in more on mobile, up 5 percentage points. The increased engagement conforms with recent data from Shareworks (also a part of Morgan Stanley at Work), which found that more companies are digitizing their equity plans.²
And they are in it for the long haul: More view their equity compensation as a long-term investment, up 3 percentage points, and also hold their equity long-term because they believe in their company’s future and performance, up 5 percentage points.
Stock plan benefits increasingly motivate key career decisions: More participants said equity awards are an important factor when deciding to remain with their company, up 5 percentage points. This view aligns with the recent Shareworks study, where plan decision-makers believe equity comp will increase in importance for compensation, recruiting, and retainment in the next five years.²
And some employees are seeking out student loan benefits: One third said their decision to accept or leave a job would be affected “quite a bit” or “very much” if their employer contributed to paying off their student loans.
Pain points persist: Taxes and achieving the maximum value of benefits are topics that continue to confound, even though understanding increased by 2 to 3 percentage points. The Shareworks study also found that understanding tax consequences is a top concern among plan decision-makers when it comes to their participants.²
Despite this year’s challenges, participants are more satisfied: Participant satisfaction with their equity compensation increased 2 percentage points, while E*TRADE’s net promoter score increased 13 percentage points.

“In a year of disruption that’s changed the nature of how many of us live and work, employees of all ages and experience levels are finding more value in their equity compensation, and in doing so are forging closer connections with their employer,” said Kate Winget, Managing Director, Head of Participant Engagement and Experience for Morgan Stanley at Work. “As we chart a path forward for economic recovery, equity compensation is emerging as a game-changing tool that can help companies create a culture of ownership and collaboration, provide traction for their workforce, and secure their teams’ actual skin in the game.”

For news and thought leadership on equity compensation, follow E*TRADE Corporate Services, on LinkedIn.

Morgan Stanley at Work and E*TRADE Corporate Services recently joined forces to further raise the bar for equity compensation, retirement solutions, and financial wellness. To learn more about E*TRADE’s equity compensation offering, visit etrade.com/corporateservices.

E*TRADE Financial Corporate Services, Inc. annual survey fielded from September 8, 2020, to September 18, 2020, to current stock plan participants of E*TRADE’s corporate clients.
Shareworks by Morgan Stanley presented the results of the 2020 State of the Equity Plan Management at Private Companies Report in a virtual event on October 21, 2020. To get a copy of the report, including full results and for more information about Shareworks by Morgan Stanley, please visit www.Shareworks.com.

About E*TRADE Financial and Important Notices

The E*TRADE Financial family of companies provides financial services, including trading, investing, banking, and managing employee stock plans. Employee stock plan solutions are offered by E*TRADE Financial Corporate Services, Inc. Securities products and services are offered by E*TRADE Securities LLC (Member FINRA/SIPC). Commodity futures products and services are offered by E*TRADE Futures LLC (Member NFA). Managed Account Solutions are offered through E*TRADE Capital Management, LLC, a Registered Investment Adviser. Bank products and services are offered by E*TRADE Bank, a Federal savings bank, Member FDIC, or its subsidiaries. More information is available at www.etrade.com.

In connection with stock plan solutions offered by E*TRADE Financial Corporate Services, Inc., E*TRADE Securities LLC provides brokerage services to stock plan participants.

E*TRADE Financial, E*TRADE, and the E*TRADE logo are trademarks or registered trademarks of E*TRADE Financial, LLC. ETFC-G

ETFC

Referenced Data

**How often do you log into ETRADE (etrade.com) to view and manage your stock plan account?***
	At least once a week	Bi-weekly	Monthly	Quarterly	Semi-annually or less often
2020	23%	12%	27%	23%	13%
2019	16%	12%	29%	26%	16%
2018	15%	11%	29%	27%	16%

*Which of the following best describes you when accessing your account using the ETRADE Mobile application?**
	2020	2019	2018
I prefer viewing my stock plan benefit information on the E*TRADE Mobile app	25%	20%	17%
I sometimes view stock plan benefit information on the ETRADE Mobile app, but prefer using the ETRADE website	27%	25%	28%
I don’t currently use the ETRADE Mobile app, and only view stock plan benefit information through the ETRADE website	47%	55%	55%

*Which one of the following best describes your approach toward selling shares or exercising options from your stock plan account?*
	2020	2019	2018
Hold stock as a long-term investment	20%	17%	22%
Sell or exercise when money is needed for a large expense	19%	21%	19%
I have never sold shares	18%	18%	15%
Sell or exercise as needed when stock reaches my targeted sell price	14%	14%	17%
Sell or exercise after waiting period to get the long-term capital gains tax rate	8%	7%	8%
Sell or exercise in increments over time	6%	6%	5%
Sell or exercise immediately upon purchase	6%	8%	10%
Do nothing	6%	6%	3%
Other	1%	1%	1%

*Why did you decide to hold your shares instead of selling them?*
	2020	2019	2018
I believe in the company’s future performance	35%	30%	72%
Hold stock as a long-term investment (e.g., retirement)	26%	27%	57%
I don’t currently have plans for (or need) the cash	20%	22%	39%
Sell or exercise when need money for a large expense (e.g., college savings)	8%	9%	15%
The company stock pays dividends	5%	5%
Other	6%	8%	2%

*Which one of the following best describes the way you think about your stock plan benefits?*
	A core part of my compensation, like my salary	Extra pay, like a bonus	A gamble that may or may not be worth something – I don’t count on it	I don’t think about my stock plan benefits
2020	21%	53%	18%	8%
2019	18%	53%	20%	9%
2018	21%	54%	16%	8%

*How well do you understand each of the following about your company’s stock plan benefits? (%Quite/Extremely Well shown)*
*Asked only for those who receive Stock Options or Stock Appreciation Rights
	2020	2019	2018
How to access my stock plan benefits account	73%	71%	70%
How my vesting schedule works	62%	59%	59%
How to sell my stock plan shares	57%
How my company’s stock plan benefits work	56%	53%	54%
Expiration date of my stock plan benefits*	52%
My potential gain or loss if I sell my stock plan shares	50%
How to find information/education about my stock plan benefits	48%	46%	45%
How to determine when to take action on my stock plan benefits	42%	41%	41%
How taxes may impact my specific type of stock plan benefits	33%	31%	31%
How to potentially maximize the financial benefit from my stock plan benefits	33%	30%	31%

*How much did your stock plan benefits factor into the following?*
		Not at all	A little	Somewhat	Quite a bit	Very much
*Your decision to accept your job*	2020	41%	13%	22%	15%	9%
	2019	46%	13%	20%	13%	7%
	2018	45%	13%	21%	13%	7%

*Your decision to stay in your job*	2020	24%	13%	22%	24%	17%
	2019	27%	14%	23%	22%	14%
	2018	28%	14%	23%	21%	14%

*If your employer contributed to paying off your student loans, how much do you think it would factor into the following?*
	Not at all	A little	Somewhat	Quite a bit	Very much
Your decision to accept your job	42%	10%	19%	16%	13%
Your decision to stay in your job	42%	10%	18%	16%	14%

*Overall, how satisfied are you with your company’s stock plan offering?*
(% = Agree/Strongly agree)
	Very dissatisfied	Dissatisfied	Neither satisfied nor dissatisfied	Satisfied	Very satisfied
2020	2%	3%	12%	48%	35%
2019	2%	3%	14%	49%	32%
2018	3%	3%	14%	49%	31%

View source version on businesswire.com: https://www.businesswire.com/news/home/20201125005593/en/

E*TRADE Media Relations

646-521-4418

[email protected]

KEYWORDS: Virginia United States North America

INDUSTRY KEYWORDS: Banking Professional Services Human Resources Finance

MEDIA:

Logo

Photo

(Graphic: Business Wire)

November 25, 2020 8:08 am

CyrusOne Inc. to Present at Investor Conferences in December 2020

CyrusOne Inc. to Present at Investor Conferences in December 2020

DALLAS–(BUSINESS WIRE)–
CyrusOne Inc. (NASDAQ: CONE), a premier global data center REIT, today announced that it will be presenting at the following virtual investor conferences in December:

Wells Fargo TMT Summit 2020, being held December 1-2, 2020. Bruce W. Duncan, President and Chief Executive Officer, will be presenting at 12:00 pm Eastern Time on Tuesday, December 1.

NASDAQ 43^rd Investor Conference being held December 1-4, 2020. Matt Pullen, EVP and Managing Director, Europe, will be presenting at 11:00 am Eastern Time on Thursday, December 3.

UBS Global TMT Conference, being held December 7-9, 2020. Bruce W. Duncan, President and Chief Executive Officer, will be presenting at 11:10 am Eastern Time on Monday, December 7.

Live webcasts of the events will be available in the “Investors / Events & Presentations” section of the Company’s website at http://investor.cyrusone.com/events.cfm. Replays will be available for 30 days following the Wells Fargo and UBS presentations and for one year following the NASDAQ presentation.

About CyrusOne

CyrusOne (NASDAQ: CONE) is a premier global REIT specializing in design, construction and operation of more than 50 high-performance data centers worldwide. The Company provides mission-critical facilities that ensure the continued operation of IT infrastructure for approximately 1,000 customers, including approximately 200 Fortune 1000 companies.

A leader in hybrid-cloud and multi-cloud deployments, CyrusOne offers colocation, hyperscale, and build-to-suit environments that help customers enhance the strategic connection of their essential data infrastructure and support achievement of sustainability goals. CyrusOne data centers offer world-class flexibility, enabling clients to modernize, simplify, and rapidly respond to changing demand. Combining exceptional financial strength with a broad global footprint, CyrusOne provides customers with long-term stability and strategic advantage at scale.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201125005417/en/

Investor Relations

Michael Schafer

Vice President, Capital Markets & Investor Relations

972-350-0060

[email protected]

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS: Data Management Commercial Building & Real Estate Technology Construction & Property REIT Security Telecommunications Software Networks Internet Hardware

MEDIA:

Logo

November 25, 2020 8:07 am

Henry Schein Announces Virtual Presence at Greater New York Dental Meeting Focused on 3D Imaging, 3D Printing, and CAD/CAM Solutions

Henry Schein Announces Virtual Presence at Greater New York Dental Meeting Focused on 3D Imaging, 3D Printing, and CAD/CAM Solutions

Company Committed to Delivering ‘Live’ Experience with Seven Booths, Daily Live Chats, Online Education, and Discussions with Industry Leaders via Facebook

MELVILLE, N.Y.–(BUSINESS WIRE)–
Henry Schein, Inc. (Nasdaq: HSIC) today announced its virtual presence at the Greater New York Dental Meeting (GNYDM), featuring dedicated booths for 3D imaging, 3D printing, and CAD/CAM solutions.

In lieu of a physical event as a result of COVID-19, visitors to Henry Schein’s seven virtual booths can explore product information, educational offerings, and industry thought-leadership events. The Henry Schein virtual experience will include an expanded portfolio of solutions including teledentistry solutions, modified practice design, and dedicated booths.

From November 27 through December 2, attendees can explore the Company’s offerings by visiting a dedicated Greater New York Dental Meeting page on Henry Schein’s website, and interact with representatives at the following virtual booths:

Henry Schein Dental (Booth #1565)
3D (CBCT) Imaging Center of Excellence (Booth #1657)
CAD/CAM & 3D Printing Center of Excellence (Booth #1557)
Practice Design (Booth #1656)
Henry Schein One (Booth #1665)
Henry Schein ProRepair (Booth #1857)
Henry Schein Professional Practice Transitions (Booth #1757)

“Every year, the Greater New York Dental Meeting gathers thousands of attendees to experience the latest innovations in dentistry, learn new techniques, and explore opportunities with education courses,” said AJ Caffentzis, President, U.S. Dental Distribution, Henry Schein. “While this year’s meeting is virtual, attendees can continue to rely on Henry Schein to deliver the best possible trade show experience, providing a comprehensive look at our innovative portfolio of solutions, a rich lineup of education courses, and engaging conversations with key industry leaders.”

Key Highlights

Henry Schein is committed to providing education, integration, and support that customers can rely on to run an efficient, successful practice. Henry Schein and its supplier partners will host a series of virtual presentations and webinars showcasing the choice of innovative, scalable digital technologies as well as business solutions that can be effectively integrated with the clinical workflow. Featured presentations include:

Technologies that can Mitigate Risk in Dentistry, Presented by Dr. Gary Severance, Executive Leader of Professional Services, Henry Schein;
From Vision to Completion: What Do You Need to Know When Building a Dental Office?, Presented by Jennifer Rhode, Manager, Dental Office Design, Henry Schein;
2020 Conebeam Review, Presented by Matt Kunzler, Digital Restoration Specialist, Henry Schein;
The Power and Potential of Digital Dentistry, Presented by Dr. Wally Renne, DMD; and
Point of Care Diagnostic Tests for the Dental Setting, Presented by Dana Becker, Strategic Business Consultant, Henry Schein; David Kochman, Vice President, Corporate Affairs and Deputy Chief of Staff, Henry Schein; and Dr. Ari Levy, MD.

“Diagnostic testing is a value-added service that dentists can provide to their patients as well as implement to help maintain a safer workplace for themselves and their staff,” said Dominick Gallo, Vice President of Process Excellence for Henry Schein Dental. “Henry Schein is making available both rapid point of care and lab-based molecular and antigen testing solutions to dental professionals. We are actively working to support dental practices in becoming licensed diagnostic labs, which will enable dentists to perform tests to address the immediate pandemic as well as the long-term need for the integration of oral health and total health.”

In addition, Henry Schein will broadcast #scheinchats, the Company’s signature social media series available on Facebook that will offer engaging conversations with perspectives from oral health professionals and industry-leading supplier partners. The GNYDM #scheinchat lineup will include:

Stanley Bergman, Chairman and CEO of Henry Schein, and Sydney Shapiro, President of the American Student Dental Association (ASDA), discussing How Dental Students are Navigating the COVID-19 Pandemic;
Dr. Bruce Lieberthal, Chief Innovation Officer of Henry Schein, and Dr. Wen Shi, Chief Executive Officer of The Forsyth Institute, discussing The Evolution of COVID-19 Diagnostic Testing;
David Kochman, Vice President, Corporate Affairs and Deputy Chief of Staff of Henry Schein, and Dr. Jessica Lee, President of the American Association of Pediatric Dentists, discussing Integrating Diagnostic Testing into the Dental Practice;
Jack Abrams, Director, Corporate Business Development, Henry Schein, and Brant Herman, Chief Executive Officer of MouthWatch, discussing The Role of Teledentistry in the Dental Practice.

Visit www.henryscheindental.com/gnydm for details on the business solutions and integrated technologies available to help dental practitioners operate a productive practice, attain business goals, and assist in the delivery of quality patient care.

About Henry Schein, Inc.

Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 19,000 Team Schein Members worldwide, the Company’s network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.

Henry Schein operates through a centralized and automated distribution network, with a selection of more than 120,000 branded products and Henry Schein private-brand products in stock, as well as more than 180,000 additional products available as special-order items.

A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 31 countries. The Company’s sales from continuing operations reached $10.0 billion in 2019, and have grown at a compound annual rate of approximately 13 percent since Henry Schein became a public company in 1995.

For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein, and @HenrySchein on Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201125005452/en/

Henry Schein, Inc.

Ann Marie Gothard, Vice President, Corporate Media Relations, [email protected], (631) 390 – 8169

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Dental Health

MEDIA:

Logo

November 25, 2020 8:05 am

Wyndham Grand to Reach New Heights with First Hotel in Australia

Wyndham Hotels & Resorts’ multi-brand expansion in Australia continues with development of a landmark 34-story tower in the heart of Adelaide’s Central Business District

PR Newswire

PARSIPPANY, N.J., Nov. 25, 2020 /PRNewswire/ — Wyndham Hotels & Resorts, the world’s largest hotel franchising company with approximately 9,000 properties across 90 countries, is ramping up its plans for expansion in Australia with the announcement of Wyndham Grand® Adelaide, a major new landmark that will become one of the tallest hotels in South Australia and the first Wyndham Grand hotel for the country when it opens in 2024.

Wyndham Grand Adelaide will rise 120 meters from King William Street in Adelaide’s Central Business District, becoming a new icon for the city. The estimated AUD150 million skyscraper is being developed by Equinox Property and will comprise some 347 contemporary rooms and suites and an extensive array of facilities, elevating the concept of approachable luxury.

“The South Australian capital has been experiencing a surge of investment, with new infrastructure projects such as the expansion of Adelaide Airport, the revamp of the Adelaide Oval, and now, the creation of one of the city’s tallest hotels,” said Joon Aun Ooi, president, Asia Pacific, Wyndham Hotels & Resorts. “We are excited to be part of this prestigious project. Wyndham Grand is known for its iconic locations, so I can think of no better way to introduce the brand to Australia.”

Wyndham Grand Adelaide will offer a selection of refined rooms and suites featuring a modern interior concept with green walls, marble fixtures and plush furnishings all accented with bold splashes of color, as well as floor-to-ceiling windows that frame breathtaking views of Adelaide’s skyline and the surrounding area.

Guests can expect a host of exceptional facilities, including an infinity pool with a sun deck and a bar offering panoramic city views, a day spa with sauna and treatment rooms, and a spacious fitness center. The five-star property will also offer a wide range of dining experiences with an upscale restaurant, a wine bar, a hills-facing sky bar with stylish alfresco seating, as well as a rooftop restaurant, which is expected to become one of the most desirable dining destinations in the city.

Wyndham Grand Adelaide is set to become the first Wyndham Grand in Australia and the wider Australasia region. It will join an exclusive collection of nearly 50 Wyndham Grand hotels and resorts worldwide. In Australia, the hotel will add to Wyndham’s rapidly expanding portfolio of brands consisting of almost 30 hotels and resorts, including locations in key cities such as Sydney, Melbourne, Perth, Brisbane, Gold Coast, Canberra and Darwin.

Wyndham Grand Adelaide will be managed by Resort Management by Wyndham Pty Ltd, a subsidiary of Wyndham Destinations, which manages a portfolio of 54 properties across the Asia Pacific, including in Australia, New Zealand, Fiji, Thailand, Indonesia and Japan.

“Our depth of hotel management experience, knowledge and capability make us the ideal partner for Wyndham Hotels & Resorts as it launches its upper-upscale Wyndham Grand brand in Australia,” said Warren Cullum, senior vice president, Operations at Wyndham Destinations Asia Pacific. “This new hotel will represent the pinnacle of hospitality available in Adelaide and we are proud to have the opportunity to provide an incomparable experience to guests and showcase Adelaide to the world.”

“This is a proud moment for our company, as we announce this landmark development with Wyndham Hotels & Resorts, one of the world’s leading hospitality companies,” commented Tong Guo, on behalf of Equinox Property. “Wyndham Grand is well-known across the world for its impressive hotels and the brand is the perfect fit for our new development. With its prime position and impressive stature, this hotel will become a new symbol of prosperity for the City of Adelaide, which has given us a place to call home the past 20 years. We are delighted that we can give back by showcasing such a significant building for the city and to all of South Australia.”

Development of Wyndham Grand Adelaide is being managed by Guava Lime Property Solutions and a competitive operator selection program for the Wyndham Grand Adelaide hotel was coordinated through Savills Hotels on behalf of Equinox Property, with support from Commercial & Legal. The hotel’s architecture is being designed by Loucas Zahos Architects.

All of Wyndham’s hotels in Australia participate in Wyndham Rewards®, the world’s most generous hotel rewards program with more than 30,000 hotels, vacation club resorts and vacation rentals worldwide.

About Wyndham Grand
Travel is the best excuse to enjoy the grand things in life. With locations in some of the world’s most sought after vacation destinations – including Shanghai, Istanbul, Doha, Salzburg and Orlando – Wyndham Grand® hotels transform ordinary moments into unforgettable experiences. Approachable by design, this upper-upscale hotel brand helps travelers make every moment count. If you are interested in developing a Wyndham Grand hotel, please visit development.wyndhamhotels.com.

About Wyndham Hotels & Resorts
Wyndham Hotels & Resorts (NYSE: WH) is the world’s largest hotel franchising company by the number of properties, with approximately 9,000 hotels across approximately 90 countries on six continents. Through its network of 804,000 rooms appealing to the everyday traveler, Wyndham commands a leading presence in the economy and midscale segments of the lodging industry. The Company operates a portfolio of 20 hotel brands, including Super 8®, Days Inn®, Ramada®, Microtel®, La Quinta®, Baymont®, Wingate®, AmericInn®, Hawthorn Suites®, Trademark Collection® and Wyndham®. Wyndham Hotels & Resorts is also a leading provider of hotel management services. The Company’s award-winning Wyndham Rewards loyalty program offers 85 million enrolled members the opportunity to redeem points at thousands of hotels, vacation club resorts and vacation rentals globally. For more information, visit www.wyndhamhotels.com.

Contact

Abigail Foo

Wyndham Hotels & Resorts
+65 9067 8040
[email protected]

View original content to download multimedia:http://www.prnewswire.com/news-releases/wyndham-grand-to-reach-new-heights-with-first-hotel-in-australia-301180510.html

SOURCE Wyndham Hotels & Resorts

November 25, 2020 8:05 am

Identity and Access Management Provider BIO-key Presents at Imperial Capital Virtual Security Investor Conference Wednesday, December 2nd

WALL, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) — BIO-key International, Inc. (Nasdaq: BKYI), an innovative provider of identity and access management (IAM) solutions powered by biometrics, today announced that its Chairman & CEO Michael DePasquale will present at the 17th Annual Imperial Capital Security Investor Conference on Wednesday, December 2, 2020 at 12:30 pm ET. The Conference will connect approximately 70 public and private security-focused companies with 500 key investors and business leaders. For health and safety reasons, this year’s conference will take place virtually over two days December 2-3, 2020.

Now in its 17th year, Imperial Capital’s Security Investor Conference remains the security industry’s leading investor conference, bringing together a select group of companies to present their positioning and strategic growth plans to key investors and business leaders. This virtual gathering of presenting companies and executives with institutional and private equity investors provides an opportunity to learn about companies delivering the latest in compelling security solutions across global Consumer, Enterprise and Government markets.

About Imperial Capital, LLC (

www.imperialcapital.com

)

Imperial Capital is a full-service investment bank offering comprehensive suite of services, including sales and trading, capital markets and restructuring, research and investment banking advisory, to institutional investors and middle market companies.

About BIO-key International, Inc. (

www.bio-key.com

)

BIO-key is revolutionizing authentication with biometric centric, multi-factor identity and access management (IAM) solutions, including its PortalGuard IAM solution, that provide convenient and secure access to devices, information, applications and high-value transactions. BIO-key’s proprietary software and hardware solutions, with industry leading biometric capabilities, enable large-scale on-premise and Identity-as-a-Service (IDaaS) solutions as well as customized enterprise and cloud solutions.

Engage with BIO-key
Facebook – Corporate:	BIO-key International
Twitter – Corporate:	@BIOkeyIntl
Twitter – Investors:	@BIO_keyIR
StockTwits:	BIO_keyIR

Investor & Media Contacts
William Jones, David Collins
Catalyst IR
212-924-9800
[email protected]

November 25, 2020 8:04 am

Lifshitz Law Firm, P.C. Announces Investigation of AKER, EMIS, HDS, IPHI, PNM, TGC, GV and UROV

PR Newswire

NEW YORK, Nov. 25, 2020 /PRNewswire/ —

Akers Biosciences, Inc. (NASDAQ GS: AKER)

Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the merger of AKER and MYMD Pharmaceuticals, Inc.

If you are a AKER investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

Emisphere Technologies, Inc. (Other OTC: EMIS)

Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of EMIS to Novo Nordisk A/S for $7.82 per share..

If you are a EMIS investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

HD Supply Holdings, Inc. (NASDAQ: HDS)

Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of HDS to The Home Depot, Inc. for $56.00 per share.

If you are a HDS investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

Inphi Corporation (NASDAQ: IPHI)

Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of IPHI to Marvell Technology Group for 2.323 Marvell shares and $66.00 in cash.

If you are a IPHI investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

PNM Resources, Inc. (NYSE: PNM)

Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of PNM to Avangrid, Inc. for $50.30 per share.

If you are a PNM investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

Tengasco, Inc. (NYSE: TGC)

Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with TGC’s agreement to merge with Riley Exploration – Permian, LLC.

If you are a TGC investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

The Goldfield Corporation (NYSE: GV)

Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of GV to an affiliate of First Reserve for $7.00 per share.

If you are a GV investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

Urovant Sciences Ltd. (NASDAQ: UROV)

Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of UROV to Sumitovant Biopharma Ltd. for $16.25 per share..

If you are a UROV investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

ATTORNEY ADVERTISING.
© 2020 Lifshitz Law Firm, P.C. The law firm responsible for this advertisement is Lifshitz Law Firm, P.C., 821 Franklin Avenue, Suite 209, Garden City, New York 11530, Tel: (516)493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact:
Joshua M. Lifshitz, Esq.
Lifshitz Law Firm, P.C.
Phone: 516-493-9780
Facsimile: 516-280-7376
Email:
[email protected]

View original content:http://www.prnewswire.com/news-releases/lifshitz-law-firm-pc-announces-investigation-of-aker-emis-hds-iphi-pnm-tgc-gv-and-urov-301180368.html

SOURCE Lifshitz & Miller Law Firm

November 25, 2020 8:04 am

Lifshitz Law Firm, P.C. Announces Investigation of ARA, BBIO, BMCH, BLDR, CIT, EV, EIDX, NAV, STND and WTRE

PR Newswire

NEW YORK, Nov. 25, 2020 /PRNewswire/ —

American Renal Associates Holdings, Inc. (NYSE: ARA)

Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of ARA to affiliates of Nautic Partners for $11.50 per share.

If you are ARA investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

BMC Stock Holdings, Inc. (NASDAQ: BMCH) –
Builders FirstSource, Inc. (NASDAQ: BLDR)

Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of BMCH to BLDR.

If you are a BMCH or BLDR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

CIT Group Inc. (NYSE: CIT)

Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of CIT to First Citizens BancShares, Inc. for 0.0620 shares of First Citizens class A common stock per share.

If you are a CIT investor, and would like additional information about our investigation, please complete the Information Request Form.

Eaton Vance Corp. (NYSE: EV)

Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of EV to Morgan Stanley.

If you are a EV or MS investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

Eidos Therapeutics, Inc. (NASDAQ: EIDX) – BridgeBio Pharma, Inc. (NASDAQ: BBIO)

Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of EIDX to BBIO for approximately $73.26 per share.

If you are a EIDX or BBIO investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

Navistar International Corporation (NASDAQ: NAV)

Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of NAV to Traton SE for $44.50 per share.

If you are a NAV investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

Standard AVB Financial Corp. (NASDAQ GS: STND)

Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of STND to Dollar Mutual Bancorp.

If you are a STND investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

Watford Holdings Ltd. (NASDAQ: WTRE)

Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of WTRE to Arch Capital Group Ltd. for $31.10 per share.

If you are a WTRE investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected].

Contact:

Joshua M. Lifshitz, Esq.

Lifshitz Law Firm, P.C.
Phone: 516-493-9780
Facsimile: 516-280-7376
Email:
[email protected]

View original content:http://www.prnewswire.com/news-releases/lifshitz-law-firm-pc-announces-investigation-of-ara-bbio-bmch-bldr-cit-ev-eidx-nav-stnd-and-wtre-301180367.html

SOURCE Lifshitz & Miller Law Firm

November 25, 2020 8:03 am

ChemPoint Selected as Distributor of DuPont Specialty Solutions Products in Mexico

PR Newswire

DOWNERS GROVE, Ill., Nov. 25, 2020 /PRNewswire/ — ChemPoint.com Inc. (“ChemPoint”), a subsidiary of Univar Solutions Inc. (NYSE: UNVR) (“Univar Solutions” or “the Company”), a global chemical and ingredient distributor and provider of value-added services, announced today that DuPont has expanded its agreement with ChemPoint for the sales and distribution of DuPont’s cellulosic and poly (ethylene oxide) offerings in industrial applications throughout Mexico.

The agreement will extend DuPont’s footprint in Mexico’s industrial market to meet the demand for cellulosic and poly (ethylene oxide) ingredients. DuPont and ChemPoint have an existing order, delivery, and service model, specifically designed to help meet customer needs in industrial applications for ETHOCEL™ ethylcellulose polymers, METHOCEL™ cellulose ethers, POLYOX™ water-soluble polymers, and WALOCEL™ CRT products. Univar Solutions and DuPont will work together to enhance the customer experience by providing a higher degree of service and support, driven by a dedicated technical marketing and sales team focused on DuPont’s cellulosic and poly (ethylene oxide) offerings in industrial applications.

The industrial cellulosics team at ChemPoint acts as an integrated extension of DuPont to facilitate customer needs for market insights, product selection, technical assistance, order placement, and fulfillment. In addition, customers receive support from ChemPoint’s customer service and supply chain professionals to help meet delivery times and provide high levels of service.

Rick Hoener, global managing director for ChemPoint, remarked, “Our goal in all regions is to enhance the customer’s buying experience and provide a high degree of service for cellulosic and poly (ethylene oxide) product requirements. As an integrated extension of DuPont, ChemPoint offers a comprehensive product portfolio and is well situated to facilitate a customer’s need for product grade optimization, technical support, order placement, and fulfillment of thickeners and film formers.”

ChemPoint’s technical expertise across multiple industry segments, understanding of customer needs, and marketing proficiency to reach new markets and applications, make it an ideal choice to support the growth of DuPont’s Specialty Solutions. “DuPont is excited to expand our partnership with ChemPoint into Mexico. ChemPoint’s unique business model helps enable us to quickly adapt to today’s shifting needs. Thanks to their unique digital capabilities, we can reach customers faster and more efficiently, and support them in numerous applications,” said Klairie Gounaridi, DuPont’s Global Specialty Solutions commercial leader.

With the addition of these technologies, ChemPoint has expanded its portfolio for the market in Mexico. Hoener added, “We are pleased with this opportunity to further expand our relationship with DuPont. With the distribution, sales, and marketing of specialty solutions in Mexico, we can further simplify and enhance the customer experience by leveraging our digital marketing and sales approach.”

About Univar Solutions
Univar Solutions (NYSE: UNVR) is a leading global specialty chemical and ingredient distributor representing a premier portfolio from the world’s leading producers. With the industry’s largest private transportation fleet and North American sales force, unparalleled logistics know-how, deep market and regulatory knowledge, world-class formulation and recipe development, and leading digital tools, the company is well-positioned to offer tailored solutions and value-added services to a wide range of markets, industries, and applications. Univar Solutions is committed to helping customers and suppliers innovate and grow together. Learn more at UnivarSolutions.com.

About ChemPoint
ChemPoint.com Inc., a wholly owned subsidiary of Univar Solutions Inc. is a unique distribution business that provides marketing and sales services for specialty and fine chemicals in North America, Europe, the Middle East, Africa, and Latin America. The company engages in exclusive product line relationships with premier manufacturers, providing tailored solutions to more than 80 supplier partners and over 200 product lines globally. For more information, visit ChemPoint.com.

About DuPont
DuPont is a global innovation leader with technology-based materials, ingredients and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, construction, water, health and wellness, food and worker safety. More information can be found at www.dupont.com.

Forward-Looking Statements
This press release includes certain statements relating to future events and our intentions, beliefs, expectations, and predictions for the future, which are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be beyond the Company’s control. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from the expectations and assumptions. A detailed discussion of these factors and uncertainties is contained in the Company’s filings with the Securities and Exchange Commission. Potential factors that could affect such forward-looking statements include, among others: the ultimate geographic spread of the COVID-19 pandemic; the duration and severity of the COVID-19 pandemic; actions that may be taken by governmental authorities to address or otherwise mitigate the impact of the COVID-19 pandemic; the potential negative impacts of COVID-19 on the global economy and our customers and suppliers; the overall impact of the COVID-19 pandemic on our business, results of operations and financial condition; other fluctuations in general economic conditions, particularly in industrial production and the demands of our customers; significant changes in the business strategies of producers or in the operations of our customers; increased competitive pressures, including as a result of competitor consolidation; significant changes in the pricing, demand and availability of chemicals; our levels of indebtedness, the restrictions imposed by our debt instruments, and our ability to obtain additional financing when needed; the broad spectrum of laws and regulations that we are subject to, including extensive environmental, health and safety laws and regulations; an inability to integrate the business and systems of companies we acquire, including of Nexeo Solutions, Inc., or to realize the anticipated benefits of such acquisitions; potential business disruptions and security breaches, including cybersecurity incidents; an inability to generate sufficient working capital; increases in transportation and fuel costs and changes in our relationship with third party providers; accidents, safety failures, environmental damage, product quality and liability issues and recalls; major or systemic delivery failures involving our distribution network or the products we carry; operational risks for which we may not be adequately insured; ongoing litigation and other legal and regulatory risks; challenges associated with international operations; exposure to interest rate and currency fluctuations; potential impairment of goodwill; liabilities associated with acquisitions, ventures and strategic investments; negative developments affecting our pension plans and multi-employer pensions; labor disruptions associated with the unionized portion of our workforce; and the other factors described in the Company’s filings with the Securities and Exchange Commission. We caution you that the forward-looking information presented in this press release is not a guarantee of future events or results and that actual events or results may differ materially from those made in or suggested by the forward-looking information contained in this press release. In addition, forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “plan,” “seek, “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe” or “continue” or the negative thereof or variations thereon or similar terminology. Any forward-looking information presented herein is made only as of the date of this press release, and the Company does not undertake any obligation to update or revise any forward-looking information to reflect changes in assumptions, the occurrence of unanticipated events, or otherwise, except as required by law.

View original content to download multimedia:http://www.prnewswire.com/news-releases/chempoint-selected-as-distributor-of-dupont-specialty-solutions-products-in-mexico-301180343.html

SOURCE Univar Solutions Inc.